A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
Norway
St Olavs Hospital, Trondheim Sweden
Falu lasarett, Falun, Dalarna County Gävle Hospital, Gävle, Gävleborg County Skåne University Hospital, Lund, Skåne County Sahlgrenska University Hospital, Gothenburg Örebro University Hospital, Örebro Karolinska University Hospital, Stockholm Norrland's University Hospital, Umeå Akademiska hospital, Uppsala Last updated February 2021